The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

pirarubicin     (9R)-7-[(2S,4S,5S,6S)-4- amino-6-methyl-5...

Synonyms: Pirarubicina, Pirarubicine, Pirarubicinum, THP-adriamycin, AC1MHVUE, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of pirarubicin


High impact information on pirarubicin


Chemical compound and disease context of pirarubicin


Biological context of pirarubicin


Anatomical context of pirarubicin


Associations of pirarubicin with other chemical compounds


Gene context of pirarubicin


Analytical, diagnostic and therapeutic context of pirarubicin


  1. Clinical pharmacology and toxicity of 4'-O-tetrahydropyranyladriamycin. Miller, A.A., Schmidt, C.G. Cancer Res. (1987) [Pubmed]
  2. Design, synthesis, and in vitro activity of catamphiphilic reverters of multidrug resistance: discovery of a selective, highly efficacious chemosensitizer with potency in the nanomolar range. Teodori, E., Dei, S., Quidu, P., Budriesi, R., Chiarini, A., Garnier-Suillerot, A., Gualtieri, F., Manetti, D., Romanelli, M.N., Scapecchi, S. J. Med. Chem. (1999) [Pubmed]
  3. Phase II study of pirarubicin (THP-adriamycin) in metastatic breast cancer patients. Lenk, H., Tanneberger, S., Wiener, N., Giesske, H., Gärtner, S., Geyer, J., Rotte, K.H. Oncology (1990) [Pubmed]
  4. The role of the proteasome in apoptosis induced by anthracycline anticancer agents. Kiyomiya, K., Kurebe, M., Nakagawa, H., Matsuo, S. Int. J. Oncol. (2002) [Pubmed]
  5. High-energy underwater shock wave treatment for internal iliac muscle metastasis of prostatic cancer: a first clinical trial. Hoshi, S., Orikasa, S., Suzuki, K., Saitoh, T., Takahashi, T., Yoshikawa, K., Kuwahara, M., Nose, M. Jpn. J. Cancer Res. (1995) [Pubmed]
  6. Pharmacokinetic and pharmacodynamic advantages of pirarubicin over adriamycin after intraarterial hepatic administration in the rabbit VX2 tumor model. Munck, J.N., Riggi, M., Rougier, P., Chabot, G.G., Ramirez, L.H., Zhao, Z., Bognel, C., Ardouin, P., Herait, P., Gouyette, A. Cancer Res. (1993) [Pubmed]
  7. Pilot study of modified version of CHOP plus radiotherapy for early-stage aggressive non-Hodgkin's lymphoma of the head and neck. Nishioka, T., Tsuchiya, K., Nishioka, S., Kitahara, T., Ohmori, K., Homma, A., Aoyma, H., Shindoh, M., Shirato, H. Int. J. Radiat. Oncol. Biol. Phys. (2004) [Pubmed]
  8. Cell cycle dependent uptake and release of anthracycline by drug-resistant and drug-sensitive human leukaemic K562 cells. Tarasiuk, J., Foucrier, J., Garnier-Suillerot, A. Biochem. Pharmacol. (1993) [Pubmed]
  9. A limited sampling strategy for the study of pirarubicin pharmacokinetics in humans. Marchiset-Leca, D., Leca, F.R., Galeani, A., Noble, A., Iliadis, A. Cancer Chemother. Pharmacol. (1995) [Pubmed]
  10. Therapeutic significance of surgery in advanced neuroblastoma: a report from the study group of Japan. Tsuchida, Y., Yokoyama, J., Kaneko, M., Uchino, J., Iwafuchi, M., Makino, S., Matsuyama, S., Takahashi, H., Okabe, I., Hashizume, K. J. Pediatr. Surg. (1992) [Pubmed]
  11. Intrapleural pirarubicin (4'-O-tetrahydropyranyladriamycin) for treatment of malignant pleural effusion. Gotoh, T., Tanaka, Y., Fujita, Y., Hiramori, N., Fujii, T., Arimoto, T., Iwasaki, Y., Fukabori, T., Nakamura, T., Ono, N., Nakagawa, M. Jpn. J. Clin. Oncol. (1996) [Pubmed]
  12. Pharmacokinetics of 4'-O-tetrahydropyranyladriamycin given on a weekly schedule in patients with advanced breast cancer. Mader, R.M., Zilg, H., Schlappack, O., Steger, G.G., Baur, M., Greifenberg, B., Heberle, U., Dittrich, C. Cancer Chemother. Pharmacol. (1995) [Pubmed]
  13. Non-competitive inhibition of P-glycoprotein-associated efflux of THP-adriamycin by verapamil in living K562 leukemia cells. Pereira, E., Borrel, M.N., Fiallo, M., Garnier-Suillerot, A. Biochim. Biophys. Acta (1994) [Pubmed]
  14. Circadian and seasonal rhythms in murine bone marrow colony-forming cells affect tolerance for the anticancer agent 4'-O-tetrahydropyranyladriamycin (THP). Lévi, F., Blazsek, I., Ferlé-Vidovic, A. Exp. Hematol. (1988) [Pubmed]
  15. Phase I clinical trial and pharmacokinetic evaluation of 4'-0-tetrahydropyranyladriamycin (THP-adriamycin). Raber, M.N., Newman, R.A., Lu, K., Legha, S., Gorski, C., Benjamin, R.S., Krakoff, I.H. Cancer Chemother. Pharmacol. (1989) [Pubmed]
  16. In vitro sensitivity of human endometrial cancer cell lines to paclitaxel or irinotecan (CPT-11) in combination with other aniticancer drugs. Hiramatsu, H.P., Kikuchi, Y., Seto, H., Nagata, I. Anticancer Drugs (2000) [Pubmed]
  17. Rapid uptake by cultured tumor cells and intracellular behavior of 4'-O-tetrahydropyranyladriamycin. Kunimoto, S., Miura, K., Takahashi, Y., Takeuchi, T., Umezawa, H. J. Antibiot. (1983) [Pubmed]
  18. Mechanism of inhibition of DNA polymerases by 4'-epiadriamycin and 4'-O-tetrahydropyranyladriamycin. Tanaka, M., Yoshida, S., Kimura, K. Gann = Gan. (1983) [Pubmed]
  19. Comparison of the membrane transport of anthracycline derivatives in drug-resistant and drug-sensitive K562 cells. Frezard, F., Garnier-Suillerot, A. Eur. J. Biochem. (1991) [Pubmed]
  20. Treatment of disseminated hepatoblastoma involving bilateral lobes. Tsuchida, Y., Bastos, J.C., Honna, T., Kamii, Y., Hori, T., Mochida, Y. J. Pediatr. Surg. (1990) [Pubmed]
  21. MDR-related properties of K 562 cells grown in two different culture media. Ferrand, V.L., Chauvet, M.M., Dell'Amico, M.H., Tsuruo, T., Hirn, M.H., Bourdeaux, M.J. Anticancer Res. (1996) [Pubmed]
  22. A possible mechanism of endothelium-dependent relaxation induced by pirarubicin and carbachol in rat isolated aorta. Hirano, S., Agata, N., Hara, Y., Iguchi, H., Shirai, M., Tone, H., Urakawa, N. J. Pharm. Pharmacol. (1992) [Pubmed]
  23. Effect of sodium chloride on pirarubicin induced cell killing in P388 mouse leukemia cells. Furusawa, S., Fujimura, T., Hayasaka, S., Kawauchi, H., Sasaki, K., Takayanagi, Y. Res. Commun. Chem. Pathol. Pharmacol. (1991) [Pubmed]
  24. Analysis of treatment outcome for children with recurrent or metastatic hepatoblastoma. Matsunaga, T., Sasaki, F., Ohira, M., Hashizume, K., Hayashi, A., Hayashi, Y., Mugishima, H., Ohnuma, N. Pediatr. Surg. Int. (2003) [Pubmed]
  25. Pharmacokinetics and disposition of 4'-O-tetrahydropyranyladriamycin in mice by HPLC analysis. Iguchi, H., Tone, H., Ishikura, T., Takeuchi, T., Umezawa, H. Cancer Chemother. Pharmacol. (1985) [Pubmed]
  26. Simultaneous adenocarcinoma of the stomach and fourth portion of the duodenum: case report and review of the literature. Kusumoto, H., Kumashiro, R., Kido, K., Inutsuka, S. Radiation medicine. (1991) [Pubmed]
WikiGenes - Universities